Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CCXI $8.67 0.8700 +11.15%
VBLT $8.05 0.6700 +9.08%
FPRX $25.64 2.1200 +9.01%
ADXS $25.16 2.0400 +8.82%
AGEN $8.18 0.5600 +7.35%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

GALT $2.51 -0.2300 -8.39%
BMY $64.60 -4.5500 -6.58%
BPTH $1.20 -0.0800 -6.25%
XBIT $19.12 -0.8000 -4.02%
GALE $1.57 -0.0600 -3.68%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

AstraZeneca and Lilly to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumours

(AstraZeneca) May 29, 2015 - AstraZeneca and Eli Lilly and Company today announced that they have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ramucirumab (CYRAMZA®), Lilly’s VEGF Receptor 2 antiangiogenic cancer medicine.
read corporate press release 

Heron Therapeutics Announces Positive Results From Phase 3 MAGIC Study Of SUSTOL®

(MarketWatch) May 28, 2015 - Primary endpoint achieved-SUSTOL, as part of a three-drug regimen, is the first 5-HT3 antagonist to demonstrate superiority to standard-of-care for delayed nausea and vomiting after HEC-SUSTOL-based regimen was associated with significantly reduced nausea and improved patient satisfaction.
read article 

ASCO '15: A Review of Cancer Rx Use and Costs

(The Express Scripts Lab blog) May 27, 2015 - Express Scripts summarizes cancer pharmacy data and forecasts in advance of the 2015 American Society of Clinical Oncology Annual Meeting in Chicago.
read article 

ASCO and ACCC Host Tutorial Webinar on Applying for the Medicare Oncology Payment Model

(ASCO in Action) May 28, 2015 - The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) are pleased to offer, "The OCM Application: Getting it Done," a tutorial webinar on completing the application for the Center for Medicare and Medicaid Innovation's (CMMI) Oncology Care Model (OCM) before the submission deadline on June 18, 2015.
read article 

Major Study Finds Earlier HIV Treatment Improves Health, NIH Says

(Fox News/Associated Press) May 28, 2015 - A major international study sought to settle how soon is best to start HIV treatment — and the advice is don't delay.
read article 

GlobeImmune Hep B Drug Fails Mid-Stage Study, Shares Plunge

(Reuters) May 27, 2015 - Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company's shares down as much as 60 percent to a record low.
read article 

Teva Settles Cephalon Case With F.T.C. for $1.2 Billion Over Sleep Drug

(New York Times) May 28, 2015 - The Federal Trade Commission announced on Thursday a record settlement of $1.2 billion with Teva Pharmaceutical Industries over charges that its subsidiary Cephalon illegally blocked generic competition to its sleep-disorder drug Provigil.
read article 

FDA Clears Two Irritable Bowel Syndrome Treatments

(Morningstar/Dow Jones Newswires) May 27, 2015 - The U.S. Food and Drug Administration has cleared two treatments for irritable bowel syndrome with diarrhea, approving drugs that are both linked to recent merger activity in the sector.
read article 

Arizona Oncology Now Offering Palliative Care For Patients in Tucson

(The US Oncology Network) May 27, 2015 - Arizona Oncology, a leader in community based cancer care and a practice in The US Oncology Network, is now offering palliative care to patients in Tucson and southern Arizona.
read corporate press release 

Roswell Park Opens Oncology-Focused Pharmacy

(RPCI) May 27, 2015 - Roswell Park Cancer Institute (RPCI) opened a new specialty pharmacy dedicated to the prescription needs of cancer patients.
read press release 

'Trip Wire': UPMC Says It Cut Highmark Members After Insurer Stopped Paying Higher Rates For Cancer Treatment

(Pittsburgh Business Times) May 27, 2015 - UPMC decided to deny some 182,000 Highmark Medicare Advantage plan members in-network access to its doctors and hospitals after the health insurer last year said it would not pay UPMC higher rates for administering cancer–fighting drugs, a lawyer for the hospital giant argued Wednesday morning.
read article 

Dean of Penn’s Perelman School of Medicine: Precision Medicine Is “Personalized, Problematic, and Promising”

(Penn Medicine) May 27, 2015 - Noting that “many physicians contend that they have always practiced individualized and personalized medicine,” the authors distinguish this new field by the rapid pace of advances in diagnostic and treatment options powered by the convergence of technological breakthroughs.
read press release 

Pfizer Announces $3 Million Grants Program to Further Clinical Research in Advanced Breast Cancer

(Benzinga) May 28, 2015 - Pfizer Inc. today announced the launch of a competitive, peer-reviewed grants program to support clinical research projects investigating IBRANCE® (palbociclib) in advanced breast cancer.
read article 

Rosetta Genomics Launches OncoGxOne™

(MarketWatch) May 28, 2015 - Rosetta Genomics Ltd., a leading developer and provider of microRNA-based molecular diagnostics, today announces the commercial launch of OncoGxOne, Admera Health’s next-generation sequencing (NGS) panel that detects a vast number of genetic alterations implicated in cancer to provide clear, concise and actionable clinical recommendations from a single, comprehensive test.
read article 

New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

(Yahoo! Finance) May 28, 2015 - Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer.
read article 

Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab)

(Merck) May 28, 2015 - Merck, known as MSD outside the United States and Canada, and NanoString Technologies, Inc. today announced a clinical research collaboration to develop an assay that will optimize immune-related gene expression signatures and evaluate the potential to predict benefit from Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in multiple tumor types.
read corporate press release 

Conquer Cancer Foundation Launches $150 Million Fundraising Campaign Ahead of World's Largest Cancer Meeting in Chicago

(CBS 8 [San Diego, CA]) May 27, 2015 - The Conquer Cancer Foundation today launched The Campaign to Conquer Cancer just days before more than 28,000 oncology professionals gather at Chicago's McCormick Place for the American Society of Clinical Oncology (ASCO) 51st Annual Meeting, which will be held May 29 to June 2.
read article 

Puma Bio Restricting Access to Breast Cancer Event at ASCO Chicago

(TheStreet) May 28, 2015 - Puma Bio, embroiled in controversy over its breast cancer drug neratinib, is turning away some people from a company event during the American Society of Clinical Oncology (ASCO) annual meeting.
read article 

ASCO President Peter Yu, MD, on Big Data, Big Themes for Upcoming Annual Meeting

(Medscape Medical News) May 27, 2015 - In advance of the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), ASCO President Peter Yu, MD, spoke with Medscape and provided a brief primer on big data, one of the major themes of this year's meeting program.
read article (free registration required) 

AB Science: Phase 2 With Masitinib in Peripheral T-Cell Lymphoma Accelerated Into Phase 3

(Yahoo! Finance) May 27, 2015 - AB Science SA announces that its phase 2 with masitinib in relapsed or refractory peripheral T-cell lymphoma (PTCL) was accelerated into a phase 3 randomized controlled trial.
read article 

Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers

(Yahoo! Finance) May 28, 2015 - Pharmacyclics, Inc. today announced the initiation of PCYC-1136-CA, a multi-center study that will investigate the use of ibrutinib (IMBRUVICA®) in combination with MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor being developed by AstraZeneca.
read article 

Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma

(CNNMoney) May 28, 2015 - Celldex Therapeutics, Inc. today announced the initiation of an open-label, Phase 1/2 safety and tolerability study examining the investigational combination of varlilumab and sunitinib (SUTENT®) in patients with metastatic clear cell renal cell carcinoma (CC-RCC).
read article 

Diagnosing Cancer With Help From Bacteria

(MIT News) May 27, 2015 - Engineered probiotics can detect tumors in the liver.
read article 

Sleeping Cancer Cells Can ‘Wake Up’ After Decades

(ICR [UK]) May 28, 2015 - Scientists believe they have explained why some cancers that appear to have been cured can recur many years or even decades later.
read press release 

Breast Cancer 'Alters Bone to Help It Spread'

(BBC News) May 28, 2015 - Researchers at the University of Sheffield said the tumours were effectively "fertilising" the bone to help themselves grow.
read article